A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity. / Hagemann, Christoffer A.; Legart, Christian; Møllerhøj, Mathias B.; Madsen, Martin R.; Hansen, Henrik H.; Kønig, Merete J.; Helgstrand, Frederik; Hjørne, Flemming P.; Toxværd, Anders; Langhoff, Jill L..; Kielgast, Urd L.; Gluud, Lise L.; Ægidius, Helene; Rigbolt, Kristoffer T.G.; Vilsbøll, Tina; Jelsing, Jacob; Knop, Filip K.
I: PLoS ONE, Bind 17, Nr. 10, e0275901, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity
AU - Hagemann, Christoffer A.
AU - Legart, Christian
AU - Møllerhøj, Mathias B.
AU - Madsen, Martin R.
AU - Hansen, Henrik H.
AU - Kønig, Merete J.
AU - Helgstrand, Frederik
AU - Hjørne, Flemming P.
AU - Toxværd, Anders
AU - Langhoff, Jill L..
AU - Kielgast, Urd L.
AU - Gluud, Lise L.
AU - Ægidius, Helene
AU - Rigbolt, Kristoffer T.G.
AU - Vilsbøll, Tina
AU - Jelsing, Jacob
AU - Knop, Filip K.
N1 - Publisher Copyright: © 2022 Hagemann et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2022
Y1 - 2022
N2 - Non-invasive biomarkers of non-alcoholic fatty liver disease (NAFLD) supporting diagnosis and monitoring disease progression are urgently needed. The present study aimed to establish a bioinformatics pipeline capable of defining and validating NAFLD biomarker candidates based on paired hepatic global gene expression and plasma bioanalysis from individuals representing different stages of histologically confirmed NAFLD (no/mild, moderate, more advanced NAFLD). Liver secretome gene signatures were generated in a patient cohort of 26 severely obese individuals with the majority having no or mild fibrosis. To this end, global gene expression changes were compared between individuals with no/mild NAFLD and moderate/advanced NAFLD with subsequent filtering for candidate gene products with liver-selective expression and secretion. Four candidate genes, including LPA (lipoprotein A), IGFBP-1 (insulin-like growth factor-binding protein 1), SERPINF2 (serpin family F member 2) and MAT1A (methionine adenosyltransferase 1A), were differentially expressed in moderate/advanced NAFLD, which was confirmed in three independent RNA sequencing datasets from large, publicly available NAFLD studies. The corresponding gene products were quantified in plasma samples but could not discriminate among different grades of NAFLD based on NAFLD activity score. Conclusion: We demonstrate a novel approach based on the liver transcriptome allowing for identification of secreted hepatic gene products as potential circulating diagnostic biomarkers of NAFLD. Using this approach in larger NAFLD patient cohorts may yield potential circulating biomarkers for NAFLD severity.
AB - Non-invasive biomarkers of non-alcoholic fatty liver disease (NAFLD) supporting diagnosis and monitoring disease progression are urgently needed. The present study aimed to establish a bioinformatics pipeline capable of defining and validating NAFLD biomarker candidates based on paired hepatic global gene expression and plasma bioanalysis from individuals representing different stages of histologically confirmed NAFLD (no/mild, moderate, more advanced NAFLD). Liver secretome gene signatures were generated in a patient cohort of 26 severely obese individuals with the majority having no or mild fibrosis. To this end, global gene expression changes were compared between individuals with no/mild NAFLD and moderate/advanced NAFLD with subsequent filtering for candidate gene products with liver-selective expression and secretion. Four candidate genes, including LPA (lipoprotein A), IGFBP-1 (insulin-like growth factor-binding protein 1), SERPINF2 (serpin family F member 2) and MAT1A (methionine adenosyltransferase 1A), were differentially expressed in moderate/advanced NAFLD, which was confirmed in three independent RNA sequencing datasets from large, publicly available NAFLD studies. The corresponding gene products were quantified in plasma samples but could not discriminate among different grades of NAFLD based on NAFLD activity score. Conclusion: We demonstrate a novel approach based on the liver transcriptome allowing for identification of secreted hepatic gene products as potential circulating diagnostic biomarkers of NAFLD. Using this approach in larger NAFLD patient cohorts may yield potential circulating biomarkers for NAFLD severity.
U2 - 10.1371/journal.pone.0275901
DO - 10.1371/journal.pone.0275901
M3 - Journal article
C2 - 36260611
AN - SCOPUS:85140415565
VL - 17
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 10
M1 - e0275901
ER -
ID: 325027165